• Both NHS and self-pay patients stayed on medication significantly longer and achieved substantial weight loss when given access to specialist digital care.
• A significant majority of NHS patients remained in treatment at 12 months, despite starting with more complex health needs.
• The findings, being presented at the 2026 UK Congress on Obesity, highlight the importance of regular clinical support, not just access to medication, in sustaining treatment and helping patients achieve long-term goals.

‍

London, United Kingdom, 2026. New data being presented today at the 2026 UK Congress on Obesity (UKCO) has shown patients are more likely to stay on medication longer and achieve significant weight loss when enrolled in a specialist digital care service. The breakthrough findings, being presented by Reset Health, experts in the personalised management of chronic disease, add to an increasing body of evidence that patient support is vital to achieving sustainable health outcomes when taking GLP-1 medication.

Up to 65% of patients taking groundbreaking weight-loss medications discontinue treatment within a year in real-world settings, leading to weight rebound and limiting the long-term potential of these therapies.

This latest study followed 180 patients for 48 weeks, with all patients receiving support from the same clinical team through the same digital service. The distinctive study model allowed researchers to compare NHS and self -pay pathways more directly through identical infrastructure. This included regular remote consultations with specialist clinicians, ongoing monitoring of side effects and dosing adjustments as needed throughout the 48 weeks. Patients also received dietary and lifestyle guidance throughout. 

The study found both NHS and self-pay patients achieved substantial weight loss by using the weight management platform. Among patients with a recorded weight at 48 weeks, average weight loss was 16.7% in the NHS group and 19.3% in the self -pay group.

NHS-funded patients were more likely to remain in care, with 84% continuing with their medication after 48 weeks. In comparison, 65% of self -pay patients continued with medication after 48 weeks. While lower than the NHS cohort, this remains well above average persistence rates of around 30-40%.

NHS patients were also more likely to remain enrolled in the wider weight-management programme. This was despite NHS patients starting treatment with a much higher average body mass index and higher rates of some health conditions, including osteoarthritis.

Professor Barbara McGowan, Co-founder and Chief Medical Officer at Reset Health, said: “These findings are further evidence that access to medication is only part of the picture when it comes to successful obesity care . “Regular clinical support is vital in helping people manage side effects, adjust treatment and continue care over the longer term.”

Dr. Laura Falvey, Head of Clinical at Reset Health added: “What this study shows is that high levels of continued treatment are possible in both NHS and self-pay services when medication is combined with structured, ongoing care.”

The abstract including the findings will be published by the Association on the Study of Obesity following the conclusion of the UKCO 2026.

ENDS

For media enquiries, contact 5654 & Company

Matthew Neal (+44 7917 800 011)

Steven Scott (+44 7904 407028 )

resethealth@5654.co.uk

Notes to Editors

The study included 180 patients who had reached 48 weeks in the programme: 80 NHS-funded patients and 100 self-pay patients. Medication persistence was defined as having a dispensing record within eight weeks of the patient’s 48 -week milestone. This shows that medication was supplied but does not confirm that every dose was taken. The study was not randomised, and the groups differed in their health needs, choice of medication and dosing. Weight measurements were not available for all patients at each follow-up point.

Study title: Twelve-month medication persistence, clinical efficacy, and dosing behaviour in self-pay versus NHS-funded incretin-based therapy pathways within the same high-engagement digital service: a comparative analysis

About Reset Health

Reset Health ( www.resethealth.clinic ) is a digital health company delivering end -to-end

management of chronic conditions by combining its Reset Technology Platform (RTP), with the latest innovative evidence -based clinical care pathways for each chronic condition it treats. Reset’s integrated care model for metabolic health, Roczen (www.roczen.com), is used in conjunction with new anti obesity medications, GLP-1s and GIPs, to enhance health outcomes of patients with obesity and associated co -morbidities.

Reset Health is regulated by the Care Quality Commission, and Roczen has been evaluated by NICE for delivering multidisciplinary weight-management services and for prescribing and monitoring weight -management medicine. The outcome is a time-limited NICE recommendation for early use within the NHS until March 2028, while further evidence is gathered. Reset Health provides care across the UK, Europe and Malaysia where its integrated care models are available to millions of patients, working with pharma, governments, employers, insurers, private providers and health systems.

www.resethealth.clinic